<DOC>
	<DOCNO>NCT01831791</DOCNO>
	<brief_summary>This multicentre , open-label study ass safety , tolerability , efficacy 0.5 mg Dutasteride administer daily 52 week men Androgenetic Alopecia type III vertex , IV V per Norwood-Hamilton classification . The study consist Screening Phase ( 3 week prior Baseline ) Treatment Phase ( 52 week ) . A subject complete full course study treatment final study visit ( Week 52 ; Visit 7 ) consider study completion .</brief_summary>
	<brief_title>A Long-term Study Determine Safety Efficacy Dutasteride Male Subjects With Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male outpatient , 20 50yearsold , inclusive ( time obtain consent ) . AGA classify Type III vertex , IV , V ( exclude Type IV anterior V anterior ) utilize NorwoodHamilton classification . Fluent literate Japanese ability comprehend record information PAS SFI DLQI questionnaire . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; =1.5 x ULN ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Willing comply study requirement , include maintain hair color hairstyle throughout study ) subject use hair colorants/hair dye may continue ; however , trace hair color remain scalp time study visit . b ) hair length nonbalding area &gt; =2 cm ( 0.75 inch ) around vertex region head time study visit . Able swallow retain oral medication Evidence hypogonadism define serum testosterone &lt; 250 Nanogram/decilitre ( ng/dl ) Screening . Unstable liver disease ( chronic stable hepatitis B C acceptable subject otherwise meet entry criterion ) . History renal insufficiency Serum creatinine &gt; 1.5 x ULN Screening . History malignancy within past 5 year , except basal cell squamous cell carcinoma skin . History prostate cancer age 50 year first degree relative . Serum PSA level &gt; 2.0 nanogram/millilitre ( ng/mL ) Screening . History breast cancer clinical breast examination suggestive malignancy . Active unstable thyroid disease , include subject therapy either hyperthyroidism hypothyroidism unless dose thyroid medication stable least 3 month . Any unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management , subject know acquired immunodeficiency syndrome [ AIDS ] ( include subject diagnosis human immunodeficiency virus ( HIV ) positive ) . History current evidence serious and/or unstable preexist medical psychiatric disorder , condition could , opinion investigator GSK medical monitor , interfere subject 's safety , obtain informed consent , compliance study procedure . Note : investigator may consult GSK medical monitor condition could interfere subject 's safety . Clinically relevant abnormal find Screening electrocardiogram ( ECG ) . Global scalp hair thin , include occipital area . Scarring scalp , include prior hair transplant scalp reduction , condition disease scalp hair , include disease hair shaft ( e.g. , tinea infection , nonandrogeneticcause alopecia , psoriatic dermatitis psoriatic lesion , uncontrolled seborrheic dermatitis ) . History hair transplantation time correct AGA use hair weave within 6 month prior Screening . History evidence hair loss AGA ( e.g. , due autoimmune , endocrine , mechanical infectious process , secondary scalp dermatological disorder ) . Use cosmetic product aim improve correct sign hair loss ( e.g. , scalp preparation claim aim improved hair growth ) within 2 week prior Screening . Use light laser treatment scalp ( e.g. , light emit diode [ LED ] lamp ) within 3 month prior Screening . Hypersensitivity 5 alphareductase ( 5AR ) inhibitor drug chemically relate study treatment . Use Dutasteride within 18 month prior Screening , use finasteride within 12 month prior Screening . Previous use systemic cytotoxic agent . Use glucocorticoid ( inhaled glucocorticoid allow ; topical corticosteroid allow provide used scalp ) within 3 month prior Screening . Use follow 6 month prior Screening : Minoxidil ( oral topical ) , Carpronium chloride , Systemic drug antiandrogenic property ( e.g. , cyproterone acetate , spironolactone , ketoconazole , flutamide , bicalutamide ) . Use ketoconazole shampoo scalp prohibit study , use Screening reason exclusion . Cimetidine prohibit study , use Screening reason exclusion , Topical estrogen progesterone , Topical prostaglandin analog scalp , Tamoxifen , Drugs potentially cause hypertrichosis ( e.g. , cyclosporine , diazoxide , phenytoin , psoralens ) , Drugs potentially cause hypotrichosis telogen effluvium ( e.g. , valproic acid ) , Anabolic steroid , Lithium phenothiazine . Participation investigational market drug device trial within 1 month prior Screening study . Including participation trial Dutasteride administration active drug ( Dutasteride finasteride ) prior Screening study . In addition , subject must participate drug device trial course study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>male pattern hair loss</keyword>
	<keyword>safety</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>efficacy</keyword>
	<keyword>hair growth</keyword>
	<keyword>Androgenetic alopecia</keyword>
	<keyword>hair restoration</keyword>
</DOC>